Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Clinical Effectiveness of Fenebrutinib in RA Patients with Methotrexate or TNFI Failure

Clinical Effectiveness of Fenebrutinib in RA Patients with Methotrexate or TNFI Failure

Presented By
Dr Stanley Cohen, Metroplex Clinical Research Center, Dallas, USA
Conference
EULAR 2019

A phase 2 study demonstrated that fenebrutinib had higher efficacy than placebo for ACR50 at week 12 in patients with rheumatoid arthritis (RA) with inadequate response to methotrexate or TNF inhibitors. Furthermore, fenebrutinib was similar to adalimumab in methotrexate-refractory patients. The safety profile of fenebrutinib was acceptable.

Fenebrutinib is an orally available highly selective inhibitor of Bruton's tyrosine kinase (BTK) with potential anti-rheumatic activity. Dr Stanley Cohen (Metroplex Clinical Research Center, Dallas, USA) et al. evaluated the efficacy and safety of fenebrutinib compared with placebo and adalimumab, in combination with low-dose methotrexate, in patients with RA [1].

This multicentre, randomised, double-blind phase 2 trial included patients with moderate-to-severe active RA with an inadequate response to methotrexate or other DMARDs (MTX-IR, cohort 1) or TNF inhibitors (TNF-IR, cohort 2). Patients from the first co...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on